InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Thursday, February 12, 2026 1 min read
Key Takeaway: InMed Pharmaceuticals has released its financial results for the second quarter of fiscal 2026. The report includes updates on the company's ongoing business activities and financial performance. Specific details regarding revenue, expenses, and future projections were not provided in the article.
Market Sentiment Analysis
Full Press Release Details
December 31,
June 30,
2025
2025
Unaudited
$
$
ASSETS
Current
Cash and cash equivalents
6,954,834
11,075,871
Short-term investments
42,675
43,384
Accounts receivable, net
182,967
465,104
Inventories, net
947,898
961,173
Prepaids and other current assets
660,280
321,747
Total current assets
8,788,654
12,867,279
Non-Current
Property, equipment and ROU assets, net
764,254
992,199
Intangible assets, net
1,538,576
1,620,562
Other assets
100,000
100,000
Total Assets
11,191,484
15,580,040
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities
1,071,871
1,404,283
Current portion of lease obligations
408,122
435,507
Total current liabilities
1,479,993
1,839,790
Non-current
Lease obligations, net of current portion
123,827
305,755
Total Liabilities
1,603,820
2,145,545
Commitments and Contingencies (Note 10)
Shareholders' Equity
Common shares, no par value, unlimited authorized shares: 2,804,186 and 2,002,186 as of December 31, 2025 and June 30, 2025, respectively, issued and outstanding
92,046,396
91,221,174
Additional paid-in capital
38,405,713
39,322,644
Accumulated deficit
(120,993,014)
(117,237,892)
Accumulated other comprehensive income
128,569
128,569
Total Shareholders' Equity
9,587,664
13,434,495
Total Liabilities and Shareholders' Equity
11,191,484
15,580,040
For the Three Months Ended
For the Six Months Ended
December 31,
December 31,
2025
2024
2025
2024
$
$
$
$
Sales
820,188
1,111,707
1,940,309
2,376,345
Cost of sales
635,994
650,813
1,352,956
1,422,038
Gross profit
184,194
460,894
587,353
954,307
Operating Expenses
Research and development
630,636
895,176
1,212,248
1,595,321
General and administrative
1,621,095
1,718,774
3,153,110
3,211,735
Amortization and depreciation
53,201
53,202
106,403
107,781
Foreign exchange loss (gain)
(18,136)
47,753
38,858
28,443
Total operating expenses
2,286,796
2,714,905
4,510,619
4,943,280
Other Income (Expense)
Interest and other income
74,379
30,536
168,144
87,630
Finance expense
-
(351,549)
-
(351,549)
Loss before income taxes
(2,028,223)
(2,575,024)
(3,755,122)
(4,252,892)
Tax expense
-
-
-
-
Net loss for the period
(2,028,223)
(2,575,024)
(3,755,122)
(4,252,892)
Net loss per share for the period
Basic and diluted
(0.51)
(3.64)
(0.95)
(6.43)
Basic and diluted
3,954,549
706,546
3,954,549
661,052
For the Six Months Ended December 31,
2025
2024
$
$
Cash provided by (used in):
Operating Activities
Net loss
(3,755,122)
(4,252,892)
Items not requiring cash:
Amortization and depreciation
106,403
107,782
Share-based compensation
45,469
52,123
Amortization of right-of-use assets
208,296
166,277
Inventory write-down
70,000
-
Interest income received on short-term investments
(774)
(874)
Unrealized foreign exchange loss
3,250
20,338
Changes in operating assets and liabilities:
Inventories
(56,725)
140,968
Prepaids and other currents assets
(337,050)
(166,237)
Accounts receivable
282,137)
90,269
Accounts payable and accrued liabilities
(332,414)
(282,778)
Lease obligations
(217,329)
(203,924)
Total cash used in operating activities
(3,983,859)
(4,328,948)
Investing Activities
Sale of short-term investments
25,156
24,002
Purchase of short-term investments
(25,156)
(24,002)
Total cash used in investing activities
-
-
Financing Activities
Proceeds from the private placement
-
1,426,216
Share issuance costs
(137,178)
(249,456)
Total cash (used in) provided by financing activities
(137,178)
1,176,760
Decrease in cash and cash equivalents during the period
(4,121,037)
(3,152,188)
Cash and cash equivalents beginning of the period
11,075,871
6,571,610
Cash and cash equivalents end of the period
6,954,834
3,419,422
SUPPLEMENTARY CASH FLOW INFORMATION:
Cash paid during the period for:
-
-
Income taxes
$
-
$
-
Interest
$
-
$
-
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Recognition of Right-of-use asset and corresponding operating lease